Food and Drug Administration
CARDIOVASCULAR AND RENAL DRUGS ADVISORY COMMITTEE
October 11, 2001
The files found on this pages are in a Portable Document Format (PDF) and are indicated by PDF to the right of the document. PDF Reader is a free download which enables viewing and printing of PDF format.
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
Introduction, Mathias Hukkelhoven, PhD, Novartis Pharmaceuticals Corporation pdf
Clinical Efficacy, Jay N. Cohn, MD, University of Minnesota Medical School pdf
Efficacy Subgroup Analyses, Jay N. Cohn, MD, University of Minnesota Medical School pdf
Diovan (valsartan) Safety, Robert Glazer, MD, Novartis Pharmaceuticals Corporation pdf
Benefit: Risk Assessment, Jay N. Cohn, MD, University of Minnesota Medical School pdf
Supporting Slides pdf